RPG Life Sciences is restructuring by selling its API business to a subsidiary, RPG Active Pharma. This aims to boost the API segment and allow focus on the core formulations business. A significant investment of ₹243.33 crore from PE partners and an acquisition of Actis Generics are key parts of this strategy.
RPG Life Sciences Restructures API Business, Secures PE Funding
RPG Life Sciences has approved the slump sale of its Active Pharmaceutical Ingredients (API) business for ₹33.55 crore to its wholly-owned subsidiary, RPG Active Pharma Limited (RPGAP).
Reader Takeaway: API business spin-off plus PE funding signals growth focus; acquisition expands capabilities.
What just happened
The company's Board of Directors has sanctioned the slump sale of the API business. This transaction is classified as an 'arm's length' related party transaction and is outside the Scheme of Arrangement, as it doesn't involve a substantial undertaking. The move is designed to enable RPG Life Sciences to concentrate on its core Formulations business while RPGAP drives growth in the API segment.
Why this matters
This strategic restructuring allows for focused growth and operational flexibility. The API business, which contributed 13.54% of revenue (₹95.06 crore) and 11.72% of net worth (₹70.92 crore) as of FY26, will now operate as a distinct entity. This structure is expected to attract further investment and facilitate expansion.
The backstory
The API business has been a consistent, though smaller, contributor to RPG Life Sciences' financials. For FY26, it represented a significant portion of the company's base, highlighting its importance before this strategic pivot.
What changes now
RPGAP will operate the API business independently. In parallel, RPGAP has entered into an Investment and Shareholders' Agreement with India Life Sciences Fund IV Domestic and Vistaject Fund. These partners will invest an initial ₹243.33 crore for approximately a 40% stake in RPGAP. Furthermore, all parties have committed to infusing up to ₹700 crore to support the API business's organic and inorganic growth.
Acquisition of Actis Generics
As part of this expansion strategy, RPGAP will acquire 100% of Actis Generics Private Limited for ₹80 crore. Actis Generics, based in Visakhapatnam and incorporated in 2012, specializes in bulk drug intermediates for key APIs like Rivaroxaban, Sitagliptin, and Apixaban. It reported a turnover of ₹48.25 crore in FY 2024-25.
Risks to watch
Investors should be aware that the final consideration for the slump sale and the Actis Generics acquisition is subject to working capital adjustments. The actual financial impact may differ from the initially stated amounts.
Peer comparison
While not directly stated in the filing, many Indian pharmaceutical companies are increasingly segmenting their businesses to achieve better focus and valuation. The strategy of creating dedicated subsidiaries for specific business verticals like APIs, especially with PE backing, is a growing trend in the sector.
Context metrics (time-bound)
- Slump Sale Consideration: ₹33.55 crore
- Initial PE Investment in RPGAP: ₹243.33 crore (for ~40% stake)
- Total PE Commitment: Up to ₹700 crore
- Actis Generics Acquisition: ₹80 crore
- API Business Revenue (FY26): ₹95.06 crore (13.54% of total)
- API Business Net Worth (Mar 31, 2026): ₹70.92 crore (11.72% of total)
- Actis Generics Turnover (FY25): ₹48.25 crore
What to track next
Shareholders should monitor the successful integration of Actis Generics and the effective deployment of the substantial capital commitment towards achieving the stated organic and inorganic growth objectives for the API business under RPGAP in the coming financial periods.